GIANT CELL ARTERITIS (GCA)
Clinical trials for GIANT CELL ARTERITIS (GCA) explained in plain language.
Never miss a new study
Get alerted when new GIANT CELL ARTERITIS (GCA) trials appear
Sign up with your email to follow new studies for GIANT CELL ARTERITIS (GCA), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo may tame rare blood vessel disease with fewer steroid side effects
Disease control CompletedThis study tested a drug called secukinumab for people with giant cell arteritis, a condition where blood vessels become inflamed. The goal was to see if adding secukinumab to a steroid taper could help patients achieve remission faster and with less steroid use. About 354 adults…
Matched conditions: GIANT CELL ARTERITIS (GCA)
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New pill could help patients with rare artery disease ditch steroids faster
Disease control CompletedThis study tested a drug called upadacitinib in 429 people with giant cell arteritis, a condition that causes swollen arteries. The goal was to see if the drug could help patients achieve remission (no symptoms) while using steroids for a shorter time. Participants received eithe…
Matched conditions: GIANT CELL ARTERITIS (GCA)
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated May 06, 2026 16:14 UTC
-
Which drug better protects GCA Patients' hearts? large study investigates
Knowledge-focused CompletedThis study looked at over 1,600 people with giant cell arteritis (GCA), a condition that causes inflamed blood vessels. Researchers compared two drugs, tocilizumab and methotrexate, to see which one better prevents major heart problems like heart attacks, strokes, or death. Using…
Matched conditions: GIANT CELL ARTERITIS (GCA)
Sponsor: Groupe français d'étude des Maladies Inflammatoires de loeil • Aim: Knowledge-focused
Last updated May 17, 2026 06:46 UTC